Mohammed Salhab, Ali Zaidi, Iffat Adeel, Sana Saeed , Zeba Aziz, Azra Raza and Michael Auerbach
We report three cases of myelodysplastic syndrome (MDS), refractory anemia with ringed sideroblasts (RARS), who responded to the anti-malarial chloroquine in combination with recombinant erythropoietin (darbepoetin alfa). All three patients either remained or achieved transfusion independence and increased their hemoglobin level by at least 1 gm/dl. Responses occurred rapidly, becoming clinically noticeable within the first 4-6 weeks from start of therapy. All patients were followed for at least a 6 months period during which they have remained transfusion independent. Chloroquine affects multiple cellular pathways, but the precise mechanism of its action in RARS
patients is unclear.
Share this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report